Andrew Mcdonald

Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 100+ healthcare professionals offering a broad range of advisory services to more than 150 corporate clients in the life sciences sector.

As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives.

Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.

Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.